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Abstract
Background
Alstr€om syndrome (AS), featuring retinal dystrophy, neuronal deafness, car-
diomyopathy, metabolic syndrome, and diffuse fibrosis, is caused by biallelic
mutations in the centrosomal protein ALMS1. Genotype–phenotype correlation
has been suggested without assessment of ALMS1 expression.
Methods
ALMS1 expression (real-time PCR and immunocytochemistry) and cilia forma-
tion (immunocytochemistry) were assessed in fibroblasts from deeply pheno-
typed volunteers diagnosed with AS recruited from a dedicated AS Service.
Exome sequencing was used in two participants without convincing biallelic
ALMS1 mutations, and BBS2 (Bardet–Biedl syndrome 2) protein expression
was assessed in one patient with biallelic BBS2 mutations. Hedgehog-induced
GLI1 expression and PDGFA signaling was assessed using quantitative real-time
PCR, immunoblotting, or immunostaining of fixed cells after stimulation.
Results
In 16 of the patient cell lines examined, ALMS1 protein was undetectable (14
with biallelic loss-of-function (LoF) mutations), and in two, ALMS1 staining
was equivocal (one with biallelic LoF mutations). In five lines, ALMS1 expres-
sion was normal using at least one fixation method (one with biallelic LoF
mutations). These differences were not accounted for by major differences in
ALMS1 mRNA expression. Exome sequencing of two participants with normal
ALMS1 expression identified biallelic LoF BBS2 mutations in one. No second,
known ciliopathy mutation was found in the other patient, who had one LoF
ALMS1 mutation. Phenotypes were milder or atypical in participants with pre-
served ALMS1 immunostaining, even when two with likely alternative genetic
diagnoses were excluded. All cells studied developed normal cilia, ALMS1 and
BBS2 mutant cells showed normal Hedgehog-induced upregulation of GLI1
expression, and PDGFA signaling was normal in ALMS1-deficient cells.
Conclusion
Milder or atypical presentations of AS should prompt genetic evaluation for
alternative, clinically overlapping ciliopathies. A subgroup of patients with bona
fide ALMS1 defects have milder phenotypes due to residual ALMS1 expression,
which may be more important than mutation site.
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Introduction
Alstr€om syndrome (AS; OMIM #203800) is a rare (c. 1
per million) autosomal recessive condition characterized
by childhood onset retinal dystrophy, neuronal hearing
loss, obesity and insulin-resistant diabetes (Marshall et al.
2007a). Since its original description infantile and adult
cardiomyopathy, renal and hepatic dysfunction have also
been recognized as important clinical features of the syn-
drome. It is known to be caused by biallelic mutations in
the ALMS1 gene (Collin et al. 2002; Hearn et al. 2002);
however, although the syndrome was first described in
1959, and although the genetic basis has been known for
more than a decade, the mechanisms linking the genetic
defect to organ dysfunction are largely unknown.
The ALMS1 gene encodes a very large, ubiquitously
expressed protein that is associated with the centrosome
and the basal body of the primary cilium (Hearn et al.
2005). This, allied to the pattern of organ dysfunction
seen, has led to Alstr€om syndrome being classified as one
of the growing number of “ciliopathies”, caused by
defects in primary cilium formation or function (Girard
and Petrovsky 2011). Primary cilia are evolutionarily con-
served, membrane-bound, microtubular projections ema-
nating from the cell surface and present on virtually all
cell types in the human body (Kim and Dynlacht 2013).
They function as signaling “antennae”, having dense
expression of receptors and channels on the ciliary mem-
brane to sense, integrate, and transduce extracellular cues
such as growth factors, hormones, odorants, and develop-
mental morphogens. Cilia play an indispensable role in
tissue development (Singla and Reiter 2006; Gerdes et al.
2009), chemosensation, thermosensation, mechanosensa-
tion, osmosensation, and photoreception (Lancaster and
Gleeson 2009; Oh and Katsanis 2012). It is therefore not
surprising that ciliary defects affect multiple organs and
cause a wide range of diseases (Fliegauf et al. 2007; Hilde-
brandt et al. 2011).
Despite the strong circumstantial case that Alstr€om
syndrome is a bona fide ciliopathy, direct evidence for cil-
iary dysfunction in Alstr€om syndrome is sparse. Cells and
tissues from affected patients have morphologically
grossly normal primary cilia (Hearn et al. 2005), although
subtle defects in stereocilia (Jagger et al. 2011), renal
tubular cells (Li et al. 2007), and hypothalamic neurones
(Heydet et al. 2013) have been described in murine mod-
els of Alstr€om syndrome. It has been speculated that loss
of ALMS1 leads to functional rather than anatomical
defects in cilia, compromising, for example, vesicle trans-
port from the Golgi apparatus to the cilium and/or
intraflagellar transport (Hearn et al. 2005; Girard and
Petrovsky 2011). It remains possible that ALMS1 plays
other roles in cells unrelated to primary cilia, however,
and that it is loss of such functions that relates to the tis-
sue pathology of Alstr€om Syndrome.
Previous genetic studies have raised the tentative pos-
sibility that there is discernible genotype–phenotype cor-
relation within Alstr€om syndrome, with associations
reported between mutations in exon 16 and early reti-
nal disease, urological dysfunction, cardiomyopathy, and
diabetes, and between mutations in exon 8 and relative
protection from renal disease (Marshall et al. 2007b).
However these studies did not assess whether any
ALMS1 protein product was produced from the mutant
alleles identified. Moreover although most of the muta-
tions in the patients reported were nonsense or frame-
shift mutations, eight missense mutations of uncertain
pathogenicity were also included (Marshall et al.
2007b).
We have now studied 23 primary dermal fibroblast
lines from patients with a clinical diagnosis of Alstr€om
syndrome, all of whom had undergone mutational analy-
sis of the ALMS1 gene. We examined ALMS1 protein
expression and ciliogenesis in an attempt to re-examine
the possibility of genotype–phenotype correlation in
Alstr€om syndrome, and, in view of the role of the pri-
mary cilium as an indispensable cellular signaling orga-
nelle (Christensen et al. 2012; Briscoe and Therond 2013),
we assessed Hedgehog and PDGFA (Platelet-derived
growth factor subunit A) signaling in a selection of
affected cells.
Materials and Methods
Clinical assessment and ethical compliance
All participants underwent clinical assessment in dedi-
cated Alstr€om syndrome clinics at Torbay Hospital, Birm-
ingham Children’s Hospital or Queen Elizabeth Hospital
Birmingham, set up in collaboration with Alstr€om Syn-
drome UK, with additional clinical and cellular phenotyp-
ing studies undertaken as part of a research study
approved by the UK National Research Ethics Committee.
All volunteers provided written informed consent, and
the study was conducted in accordance with the princi-
ples of the declaration of Helsinki. Diagnostic testing of
the ALMS1 (NM_015120.4) gene was performed in
accredited diagnostic laboratories, with all mutations now
numbered with reference to ALMS1 canonical transcript
ENST00000613296.4.
Skin biopsies, establishment and
maintenance of primary dermal fibroblasts
Punch skin biopsies were taken from the flank, before
disaggregation and culture in Dulbecco’s modified Eagle
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Medium (DMEM; D6546, Sigma-Aldrich, Haverhill, UK)
supplemented with 10% fetal bovine serum (SV30180.03,
GE Healthcare Bioscience, Buckinghamshire, UK), 2 mM
L-glutamine (G7513, Sigma-Aldrich, Haverhill, UK), and
1% penicillin–streptomycin (P0781, Sigma-Aldrich,
Haverhill, UK) in a humidified incubator (37°C, 5%
CO2). Cells were passaged once weekly with 1:4 splitting.
Immunofluorescence analysis of ALMS1
expression and ciliogenesis
Fibroblasts prepared on coverslips were serum starved
for 24 h to induce cilia formation. Cells were then
fixed using one of two approaches as indicated. In the
first, they were fixed in 4% paraformaldehyde in PBS
for 10 min followed by one wash with TBS [50 mM
Tris–HCl (pH7.4), 150 mM NaCl], permeabilization in
0.2% Triton X-100 in PBS for 5 min, three washes with
TBS and quenching in fresh 0.1% sodium borohydride
in TBS for 5 min. Alternatively, cells on coverslips were
fixed with 100% methanol (prechilled to 20°C) for
10 min followed by three washes with TBS and quench-
ing in fresh 0.1% sodium borohydride in TBS for
5 min. Coverslips were blocked with blocking buffer
(10% horse serum, 1% BSA, 0.02% NaN3, 19 PBS) for
1 h, washed with TBS, and incubated with anti-ALMS1
(ab84892, abcam, Cambridge, UK) and anti-acetylated
tubulin (T7451, Sigma-Aldrich, Haverhill, UK), anti-c-
tubulin (T5326, clone GTU-88, Sigma-Aldrich, Haver-
hill, UK), anti-Smoothened (ab72130, abcam, Cam-
bridge, UK), anti-PDGFR-a (sc-338, Santa Cruz, via
Insight Biotechnology, Wembley, UK), or anti-phos-
phor-MEK1/2 (#9121, Cell Signaling Technologies, Lei-
den, The Netherlands) in 1% BSA in TBS overnight at
4°C. After washing, the cells were incubated with
1:1000 dilution of Alexa Fluor 488 goat anti-mouse
IgG (A11001, Invitrogen, via Thermo Fisher Scientific,
Hemel Hempstead, UK) and Alexa Fluor 555 goat
anti-rabbit IgG (A21430, Invitrogen, via Thermo Fisher
Scientific, Hemel Hempstead, UK) for 45 min at room
temperature in the dark, washed with TBS, mounted
on glass slides using the ProLong Gold Antifade
Reagent with DAPI (P36931, Invitrogen, via Thermo
Fisher Scientific, Hemel Hempstead, UK) and inspected
with a Zeiss LSM510 Meta (Carl Zeiss Microscopy) or
Leica TCS SP8 confocal laser scanning microscope
(Leica Microsystems, Milton Keynes, UK).
Hedgehog and PDGFA signaling pathway
assay
Fibroblasts were serum starved for 24 h in DMEM con-
taining 0.5% BSA (A8412, Sigma-Aldrich, Haverhill, UK),
2 mM L-glutamine, and 1% penicillin-streptomycin. Cells
were then treated with 1 lM SAG (Smoothened agonist,
566661, Calbiochem, San Diego, USA), 0.25 lg/mL SHH
(1845-SH-025, R&D Systems, Abingdon, UK), or 50 ng/
mL PDGF-AA (W1800950002, BIOCHROM AG, Berlin,
Germany) in serum-free DMEM for 24 h. Cells were
either fixed for immunofluorescence analysis as above or
harvested for western or qRT-PCR analysis.
Western blot analysis
Cells were washed with ice-cold PBS and harvested in M-
PER Mammalian Protein Extraction Reagent (78503,
Thermo Fisher Scientific, Hemel Hempstead, UK) con-
taining freshly added protease inhibitor mini complete
cocktail (11 836 153 001, Roche, via Sigma-Aldrich,
Haverhill, UK). Lysates were mixed with equal volume of
29 Laemmli Sample Buffer (1610737, Bio-Rad Labora-
tories, Watford, Hertfordshire, UK) and denatured at
100°C before being resolved by SDS-PAGE and trans-
ferred to PVDF membranes using the iBlot system (Invit-
rogen, via Thermo Fisher Scientific, Hemel Hempstead,
UK). Blots were blocked in TBST (50 mM Tris-HCl,
pH7.6, 150 mM NaCl, 0.1% Tween-20) containing 5%
milk or BAS and probed overnight at 4°C with the fol-
lowing antibodies: anti-BBS2 (11188-2-AP, proteintech,
Manchester, UK) anti-GLI1 (#3538, Cell Signaling Tech-
nologies, Leiden, The Netherlands), anti-GLI2 (#2585,
Cell Signaling Technologies, Leiden, The Netherlands),
anti-GLI3 (MABS275, Millipore, Watford, UK), anti-
PDGFRA (sc-338, Santa Cruz, via Insight Biotechnology,
Wembley, UK), anti-MEK1/2 (#9122, Cell Signaling Tech-
nologies, Leiden, The Netherlands), anti-phosphor-MEK1/
2 (#9121, Cell Signaling Technologies, Leiden, The Neth-
erlands), or anti-phospho-AKT (#5102, Cell Signaling
Technologies, Leiden, The Netherlands). Horseradish per-
oxidase-conjugated secondary antibodies were used fol-
lowed by Immobilon Western Chemiluminescent HRP
Substrate (WBKLS0500, Millipore, Watford, UK).
mRNA quantification
Total cellular RNA was prepared using RNeasy Mini Kits
(Qiagen, Manchester, UK) with a DNase digestion step
included. First strand cDNA was reverse-transcribed from
400 ng of total RNA using an ImProm-II Reverse Tran-
scription System (A3800, Promega, Southampton, UK)
with random hexamer primers.
Quantitative real-time PCR was carried out using an
ABI PRISM 7900 Sequence Detection System (Applied
Biosytems, via Thermo Fisher Scientific, Hemel Hemp-
stead, UK) with a SYBR Green PCR Master Mix
(4309155, Applied Biosystems) and gene-specific primers.
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Primers were custom-designed and synthesized by Sigma:
GLI1 forward primer (50 to 30) GGCTGCAGTAAAGCC
TTCAG, GLI1 reverse primer (50 to 30) GCAGCCAG
GGAGCTTACATA, HPRT1 forward primer AGTTCTGT
GGCCATCTGCTT, and HPRT1 reverse primer TAGGAA
TGCAGCAACTGACA. For every gene analyzed dissocia-
tion curve analysis was undertaken. Samples were run in
duplicate, and standard curves were constructed using
serially diluted pooled cDNA. HPRT1 was used as an
endogenous loading control after verification that its
expression was equal between treated and untreated
dermal fibroblasts.
DNA sequencing
Exome sequencing was undertaken by Oxford Genome
Technologies. In brief, DNA samples were prepared
according to Agilent’s SureSelect Protocol Version 1.2
with enrichment carried out according to Agilent SureS-
elect protocols, and sequencing undertaken on the Illu-
mina HiSeq2000 platform using TruSeq v3 chemistry.
Read files (Fastq) were generated via the manufacturer’s
proprietary software, reads were mapped to the hg19/b37
build of the human genome using the Burrows-Wheeler
Aligner (package, version 0.6.2, and mapped reads were
realigned around potential insertion/deletion (indel) sites
with the Genome Analysis Tool Kit (GATK) version 1.6.
Duplicate reads were marked using Picard version 1.107
and additional BAM file manipulations were performed
with Samtools 0.1.18. Base quality (Phred scale) scores
were recalibrated using GATK’s covariance recalibration.
SNP and indel variants were called using the GATK Uni-
fied Genotyper for each sample. All variants with poten-
tially serious functional consequences (defined as
nonsense, missense, or indel mutations within coding
sequence, or those affecting essential splice sites) or affect-
ing genes previously curated as part of the ciliary pro-
teome (van Dam et al. 2013) were then selected.
For Sanger confirmation of mutations detected by
exome sequencing, PCR amplification of genomic DNA
was performed using M13-tagged primers specific to the
BBS2 (NM_031885.3) gene. PCR products were examined
by 1% agarose gel followed by Exo1/SAP treatment.
Sequencing reactions were performed with M13 primers
using BigDye terminator (4336919, Applied Biosystems)
according to the manufacturer’s protocol. Sequencing
extension products were purified using BigDye cleaning
beads (BCB-100, MCLAB) and then analyzed with an
ABI3730 DNA analyzer. DNA sequence data were ana-
lyzed with Sequencher software (Gene Codes Corporation,
Ann Arbor, USA). Assessment of possible functional con-
sequences of missense variants in ALMS1 was performed
using the Combined Annotation Dependent Depletion
(CADD) Tool v1.3 (http://cadd.gs.washington.edu/score)
(Kircher et al. 2014).
Statistical analysis
Statistical analyses were performed in GraphPad Prism
5.0 (GraphPad Software, San Diego, CA, USA). Statistical
significance was determined by pairwise comparisons
using a two-tailed unpaired Student’s t test with a
P < 0.05 being considered significant. All data are pre-
sented as means  SEM.
Results
Cohort studied
All volunteers studied had a clinical diagnosis of Alstr€om
syndrome, and were recruited from a dedicated multidis-
ciplinary national clinical service (www.alstrom.co.uk)
(Van Groenendael et al. 2015). A summary of the demo-
graphic characteristics of the cohort studied is given in
Table S1. All had previously undergone diagnostic genetic
testing of the ALMS1 gene in different diagnostic labora-
tories, with 13 different nonsense mutations, 8 different
frameshift mutations, and 5 different missense variants
reported clinically (Table 1). Seventeen patients had bial-
lelic nonsense or frameshift mutations, and two patients
had heterozygous nonsense or frameshift mutations. Two
patients were compound heterozygous for a frameshift or
nonsense mutation and the same missense variant,
p.Asn1787Asp, and one for a frameshift variant and the
p.Asn2945Lys missense variant. Finally, one patient was
compound heterozygous for two missense variants
(p.His3881Tyr and p.Val423Ile) (Joy et al. 2007), and one
patient was heterozygous for one missense variant
(p.His624Arg). All variants had been reported as patho-
genic on clinical testing.
ALMS1 expression and ciliogenesis in
primary dermal fibroblasts
Immunofluorescent staining using two different cell fixa-
tion methods (namely 4% paraformaldehyde or metha-
nol) and a specific anti-ALMS1 antibody was first
employed to examine ALMS1 expression in primary der-
mal fibroblasts derived from all volunteers studied. The
ALMS1 antibody used has been employed in many previ-
ously studies, and was validated by showing loss of stain-
ing in HEK-293 cells after shRNA-mediated ALMS1
knockdown (data not shown). As the large majority of
the ALMS1 mutations reported in this group produced
premature stop codons resulting in truncated proteins, we
selected an antibody that was raised against a synthetic
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peptide corresponding to a region within amino acids
1200–1250 of human ALMS1 to ensure that any surviving
truncated proteins in cells with premature stop mutations
after this point in the protein were detected. Figure 1
shows representative images for positive, negative, or
weak positive ALMS1 detections in both
Figure 1. Representative immunofluorescent
images of primary dermal fibroblasts (A) Cells
fixed with 4% paraformaldehyde or methanol
followed by coimmunostaining with anti-
ALMS1 and anti-acetylated tubulin (Acet Tub).
Arrows indicate localization of ALM1 which
colocalizes with centrosomes/basal body of the
primary cilium. Representative examples of
appearances of “positive” (healthy control and
P10), “negative” (P1 and P23), and “weak”
(P2 and P1) detection are shown. Only merged
images are shown. Individual channel and
merged images as well as images stained with
anti-c-tubulin antibodies can be seen in
Figure S1. Scale bars indicate 5 lm.
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paraformaldehyde- and methanol-fixed cells. We noticed
that ALMS1 protein expression can be more readily
detected in methanol-fixed cells compared to
paraformaldehyde-fixed cells. For example, in methanol-
fixed P1 and P16 cells, ALMS1 was readily visible
(although weak compared to positive controls) but in the
paraformaldehyde-fixed cells, ALMS1 showed a negative
detection (see Figure S2B,C for ALMS1 staining intensi-
ties measured in representative positive, negative, and
weak ALMS1-expressing cells). Only three of the convinc-
ing truncating mutations in the patients studied occurred
before this epitope (Table 1). Of 23 cell lines assessed, 16
(69.6%) showed no evidence of ALMS1 staining after
either paraformaldehyde or methanol fixation; 14 of these
cell lines harbored biallelic nonsense or frameshift muta-
tions, while the remaining line from patient 8 (P8) har-
bored only one convincing pathogenic mutation. Two out
of twenty-three (8.7%) lines, one harboring a frameshift
and a nonsense mutation (P1), and one with a nonsense
mutation and a missense variant (P16; the missense vari-
ant is p.Asn1787Asp; found in 1.4% of alleles in the ExAC
exome dataset) showed equivocal staining for ALMS1
protein. Notably, however, cells from P11, harboring the
same p.Asn1787Asp variant together with a frameshift
mutation (p.Thr3591Lysfs*6) showed no immunode-
tectable ALMS1 expression; 5/23 (21.7%) lines showed
normal ALMS1 expression using one of two fixation
methods. One of these (P21) had biallelic nonsense or
frameshift mutations, one (P2) was compound heterozy-
gous for a frameshift mutation and a missense variant
(p.Asn2945Lys), one was heterozygous for a single frame-
shift mutation (P7), and two had only three missense
variants between them (P6 was compound heterozygous
for p.His3881Tyr and p.Val423Ile (Joy et al. 2007), and
P10 was heterozygous for p.His624Arg). The missense
variants had been deemed to be pathogenic in clinical
testing, but were found at allele frequencies of between
0.1 and 1.9% in the ExAC exome dataset (Table 1) (Lek
et al. 2016).
Immunocytochemistry thus stratified the patients stud-
ied into three groups defined by absent ALMS1 detection,
equivocal ALMS1 detection (about 30% of normal
ALMS1 staining intensity, e.g., in methanol-fixed P1 and
P16 cells, see Figure S2B), and normal ALMS1 detection
using one of two fixation protocols. In order to see
whether the variability between the expression levels of
nonsense mutations in ALMS1 (e.g., in P1, P16) is related
to differences in the extent of nonsense-mediated mRNA
decay (NMD) (Lindeboom et al. 2016) of the ALMS1
mRNA, we performed TaqMan assay using two sets of
primers/probes, spanning, respectively, exon 4 and exon
5, and exon 13 and exon 14 of ALMS1 gene (see Fig-
ure S3). Indeed, the relative expression levels of ALMS1
mRNA in P6, P10, and P21 which all showed positive
ALMS1 protein detections in immunocytochemistry were
higher than the rest of the lines analyzed. The relative
expression levels of ALMS1 mRNA in P5, P8, P18, P22,
and P23 (all showed negative ALMS1 protein detections)
were relatively low (Figure S3). It is therefore conceivable
that the variability between the expression levels of non-
sense mutations in ALMS1 might be related to differences
in the extent of nonsense-mediated mRNA decay (NMD)
of the ALMS1 mRNA (Lindeboom et al. 2016).
Correlations between ALMS1 genotype and cell phenotype
on one hand, and between clinical phenotype and cell
phenotype on the other, were then assessed. Although the
age at onset of many components of the syndrome was
not precisely documented in most cases, age at onset of
nystagmus, photophobia, and deafness were accurately
recorded in clinical files. The age at the former was sub-
stantially later in patients with normal ALMS1 staining
(median 120 (range 3–360) months compared to <3 (1–
48) in those with no detectable ALMS1 protein), and
hearing was also relatively preserved compared to those
with no ALMS1 staining. Moreover even in P2, whose
cells showed normal ALMS1 staining, and who was
recorded to have nystagmus and photophobia around
3 months old, visual acuity remained at 6/36 at the age of
24 years old, highly atypically for Alstr€om syndrome. No
clear differences in other components of the syndrome
were discernible, however.
Viewed from the perspective of molecular genetic test-
ing results, 14 of the 16 cell lines with biallelic nonsense
or frameshift mutations in ALMS1 had undetectable
ALMS1 staining, either focally at the centrosome or more
diffusely in the cell, suggesting that a large majority of
truncating ALMS1 alleles are not expressed at the protein
level. In one line, nearly normal staining was seen, sur-
prisingly, while in one further line equivocal staining was
observed. In both cases, this staining was seen at the cen-
trosome rather than diffusely distributed. The two
patients with clearly visible ALMS1 cellular staining did
have a later onset or more indolent course of visual
symptoms.
Two cell lines harbored a heterozygous nonsense or fra-
meshift mutation, with no second mutation reported in
either. ALMS1 expression was undetectable in the cells
with the heterozygous nonsense mutation, from P8, con-
sistent with the presence of an undetected second muta-
tion abolishing expression. The cells which had a
heterozygous frameshift mutation, from P7, showed
nearly normal ALMS1 staining, in contrast. This patient
had a milder phenotype than other patients with convinc-
ing biallelic ALMS1 mutations, and also reported two sib-
lings with cardiomyopathy, blindness and deafness. No
family members were available for study.
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Five cell lines had been reported to harbor at least one
pathogenic missense mutation. Two, P11 and P16, had
the same missense variant, p.Asn1787Asp, coinherited
with either a frameshift or a nonsense mutation, while P2
has the p.Asn2945Lys variant coinherited with a frame-
shift mutation. In P11, no ALMS1 staining was seen, in
P16, staining was only equivocal, and in P2, it was nearly
normal; however, the associated clinical syndromes were
each typical of Alstr€om syndrome. Finally, two cell lines
were from patients in whom only missense variants in
ALMS1 had been reported. One line was established from
P6, a previously published patient with compound
heterozygous ALMS1 variants, p.His3881Tyr and
p.Val423Ile, while the second was from P10, a patient
who was heterozygous for the p.His624Arg variant only.
All three of these variants have been shown to be rela-
tively common in large populations (0.1%, 0.3% and
1.9%, respectively, in ExAC), a panel of predictive algo-
rithms predicted none of them to be pathogenic
(Table S3), and ALMS1 expression in both cell lines har-
boring these variants was normal. The age of onset of eye
symptoms of Alstr€om syndrome was strikingly later in
these patients than the rest of the cohort.
As well as using anti-ALMS1 antibody to stain ALMS1
in all 23 cell lines studied, an anti-acetylated tubulin anti-
body was also used to stain cytoplasmic microtubules and
ciliary axonemes, with anti-c-tubulin antibody to stain
centrosomes (Hearn et al. 2005). All cell lines showed
normal primary cilia formation with no discernible
defects in ciliary morphology compared to healthy control
cells (Fig. 1 and Table 1; also see Figure S2A for ciliary
length measured in selected representative AS cell lines).
Exome sequencing in atypical patients
Based on preserved ALMS1 detection in cellular studies,
mild and/or atypical clinical phenotypes, and lack of two
convincingly pathogenic ALMS1 mutations, it was
hypothesized that volunteers P6, P7, and P10 may harbor
additional, or alternative, pathogenic mutations that had
not been detected hitherto. Two of these three volunteers,
patients P6 and P7, consented to exome-wide sequencing
to address this possibility.
In patient P6, whose clinical syndrome had previously
been reported and attributed to the ALMS1 missense
mutations (Joy et al. 2007), this analysis revealed two
rare and highly likely pathogenic heterozygous mutations
in BBS2, one affecting the intron 5 splice acceptor site
(c.613-1G>C) and the other the intron 6 splice donor
site (c.717 + 1G>A). The mutations were confirmed by
Sanger sequencing of genomic DNA (Fig. 2B). PCR
amplification of cDNA derived from fibroblasts using
primers flanking exon 6 of BBS2 revealed that exon 6
was absent (Fig. 2C,D), indicating that the mutations
identified were on different alleles, and also abolishing
normal exon 6 splicing, while western blotting showed
no expression of full length BBS2 protein in the cells
(Fig. 2E). A weakly detected smaller band that was not
present in control cells may, however, represent low
levels of expression of mutant BBS2 protein lacking exon
6 (Fig. 2E).
In patient P7, in contrast, no convincing biallelic
mutations were identified in any known human ciliopa-
thy gene, although the previously detected ALMS1
p.Ser3960Phefs*12 mutation was confirmed together
with a common single amino acid insertion in a minor
transcript of ALMS1 (rs147096460; p.524insPro; allele
frequency 0.63 in ExAC). To address the possibility of a
digenic cause of the patient’s phenotype, exome
sequence data were interrogated to identify all rare vari-
ants in genes assembled in a highly curated ciliary pro-
teome (van Dam et al. 2013). Eleven homozygous
variants were thus identified, while in three genes aside
from ALMS1, two or more different variants were
detected. Possible compound heterozygous and a subset
of the most damaging of the other mutations were con-
firmed by Sanger sequencing. However, while the
genetic background of possible contributing mutations
in ciliary genes was thus defined, as shown in Table S2,
no convincing digenic effect could be established by
study of one patient alone. No copy number variants
were identified in any ciliary gene on analysis of exome
data.
Hedgehog signaling in dermal fibroblasts
In mammalian cells, Hedgehog signaling requires the
primary cilium. The Hedgehog receptor Patched 1
(PTCH1) is enriched in and around the primary cilium,
where it inhibits Smoothened (SMO) activity. In the
absence of sonic hedgehog (SHH), at the base of cilia,
the GLI1 proteins GLI2 and GLI3 are phosphorylated by
a kinase complex consisting of PKA, CSNK1A1 (aka
CK1), and GSK3B. This results in their proteolytic cleav-
age to generate the repressor forms (GLI2R and GLI3R,
respectively). In the presence of SHH ligand, PTCH1 is
internalized and degraded; as a result SMO is phospho-
rylated and translocated into the primary cilium where
it helps preventing the GLI proteins from proteolytic
processing. The full length, activated GLI proteins
(GLI2A and GLI3A, respectively) eventually migrate into
the nucleus and activate target gene expression (Briscoe
and Therond 2013). Transcription of GLI1 in response
to hedgehog is thus a widely used biomarker for
increased canonical hedgehog signaling activity (Robbins
et al. 2012).
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Figure 2. Analysis of P6 dermal fibroblasts.
(A) Immunofluorescence staining of P6
fibroblasts revealing positive detection of
ALMS1 and the primary cilium. Scale bars
indicate 5 lm. (B) Sanger sequencing
confirmation showing heterozygous mutations
at the BBS2 (NM_031885.3) intron 5–6 splice
acceptor site and intron 6–7 donor site.
(C) Schematic representation of PCR analysis
strategy, with a pair of primers flanking exon 6
giving rise to a product of predicted size 813
base pairs (bp) for the wild type and 708 bp
for the mutant gene. (D) 1% agarose gel
revealed a single PCR product of predicted size
for control and the patient cells, respectively.
(E) Lack of wild type BBS2 protein in the
patient cells, as opposed to the control cells
revealed by western blot analysis. (F) qPCR
analysis of GLI1 expression (arbitrary unit: AU)
in control and patient cells following 24 h
serum starvation and subsequent 24 h SAG
treatment with housekeeping gene HPRT1 as
loading control. Results are reported as mean
values  SEM and are expressed as fold
change with respect to untreated controls,
arbitrarily set as 1; **P < 0.01.
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Figure 3. Hedgehog and PDGFA signaling
assay (A) Transcriptional induction of GLI1 in
serum-starved cells exposed to Hedgehog
(SHH) or Smoothened agonist SAG treatment
for 24 h. Dermal fibroblasts derived from one
control and one patient (P22) which showed
no ALMS1 detection by immunofluorescent
staining were used. GLI1 expression was
determined by quantitative RT-PCR and is
expressed in arbitrary units (AU). **P < 0.01,
***P < 0.001. (B) Immunoblotting for PDGFRA
of cells harvested at the indicated times during
serum starvation. (C) Phosphorylation of MEK1/
2 and AKT in response to PDGF-AA treatment
of serum-starved cells. Loading was assessed
by Coomassie blue staining. (D) Localization of
PDGFRA and phospho-MEK1/2 in serum-
starved dermal fibroblasts assessed by
immunofluorescent staining (E) Localization of
PDGFRA and phospho-MEK1/2 in serum-
starved dermal fibroblasts treated with PDGF-
AA. Scale bars indicate 5 lm.
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To assess whether Hedgehog signaling is compromised
by lack of ALMS1 at the basal body of cilia in dermal
fibroblasts, we assessed the response to serum starvation
followed by SHH or the SHH pathway agonist SAG
treatment of healthy control cell line, an AS cell line
with no detectable ALMS1 expression, and cells from
the patient we identified with biallelic BBS2 mutations.
We analyzed SMO translocation, proteolytic cleavage of
GLI proteins, and GLI1 expression by, respectively, west-
ern blotting and qRT-PCR. No proteolytic processing of
GLI proteins was detected in any of the cells studied,
likely due to low GLI protein expression. However, GLI1
mRNA expression was increased significantly in all three
cell lines by SHH (twofold increase) or SAG treatment
(ninefold increase) (Figs 3A and 2F). These findings not
only suggest that ALMS1 protein at the basal body of
the primary cilium is not critically involved in Hedgehog
signaling, but also that the BBS2 mutations we describe
in patient P6 are not sufficient to abolish ciliary func-
tion (Fig. 2F).
PDGFA signaling in dermal fibroblasts
As a further test of cell signaling mediated by the primary
cilium, we also examined PDGFA signaling in control
and ALMS1-deficient cells, as PDGFA signaling has been
shown to be regulated through the primary cilium in
fibroblasts (Schneider et al. 2005). Healthy control and
AS patient dermal fibroblasts were serum starved for 24 h
followed by treatment with PDGF-AA. As shown in
Fig. 3B, PDGFRA (platelet-derived growth factor receptor
alpha) was upregulated by serum starvation in both
healthy control and patient cells. Localization of PDGFRA
to primary cilia was not evident, however (Fig. 3D).
Phosphorylation of downstream signaling molecules such
as MEK1/2 and AKT upon stimulation with PDGF-AA
was observed in both control and AS patient cells
(Fig. 3C). Moreover, similar to prior observations (Sch-
neider et al. 2005) phosphorylated MEK1/2 was detected
mainly at the basal body with some in the primary cilia
as well (Fig. 3E). No difference in phospho-MEK1/2
localization was observed between healthy control and AS
patient cells. Taken together, these findings suggest that
ALMS1 is not critically involved in the PDGFA signaling
pathway.
Discussion
We have studied 23 patients attending a national special-
ized clinic for Alstr€om syndrome (Van Groenendael et al.
2015). The spectrum of clinical severity was approxi-
mately in keeping with prior reports of the natural history
of the syndrome (Michaud et al. 1996; Russell-Eggitt
et al. 1998; Marshall et al. 2005; Mokashi and Cummings
2011; Paisey 2013). Disease severity is difficult to quantify,
however, with many of the pleiotropic features of the syn-
drome remaining occult until detailed medical assessment,
meaning that time of onset is often imprecisely estab-
lished. In most patients nystagmus and photodysphoria
related to retinal disease are noticed early and remem-
bered, and these serve as a potentially useful semiquanti-
tative index of disease severity. We have now assessed this
index of disease severity in the context of cellular studies
as well as molecular genetic testing, allowing testing of
putative genotype–phenotype correlations with a higher
degree of confidence than has been possible hitherto in
studies where the consequence of the nucleotide change
for protein expression was uncertain.
Truncating mutations may give rise to proteins that are
unstable, and thus abolish protein expression, or may give
rise to stable truncated proteins with perturbed function.
In the case of ALMS1, loss of the centrosome-targeting
domain at the C terminus would be expected to lead to
preservation of cellular ALMS1 staining, but with a dif-
fuse pattern, if the truncated protein were expressed
(Knorz et al. 2010). In 14 of the 16 cell lines we studied
with biallelic nonsense or frameshift ALMS1 mutations,
however, no ALMS1 staining was visible, consistent with
absent protein expression. In one line nearly normal
staining was seen, surprisingly, while in one further line
equivocal staining was observed. It was not possible to
discern whether this was due to expression of a truncated
protein, or readthrough (Dabrowski et al. 2015) of the
premature stop codon to yield full length protein. The
patient with clearly visible ALMS1 cellular staining,
although having unequivocal Alstr€om syndrome, did
show a later onset and more indolent course of visual
symptoms.
Many examples of patients with a clinical diagnosis of
Alstr€om syndrome but with only one convincing patho-
genic mutation have been reported (e.g., Marshall et al.
2015), and it is usually assumed that another undetected
mutation, most likely either affecting a noncoding cis reg-
ulatory element, or resulting in a larger intragenic indel,
is present. We found undetectable ALMS1 expression in
one cell line with a heterozygous nonsense mutation, con-
sistent with this; however, the other cell line with a
heterozygous frameshift mutation showed nearly normal
ALMS1 staining. Exome-wide sequencing in this patient
showed only a common polymorphism in a minor
ALMS1 splice variant, but did delineate a range of other
sequence variants present in known ciliopathy genes. This
patient had a milder phenotype than other patients with
convincing biallelic ALMS1 mutations, and also reported
two siblings who were not available for study with car-
diomyopathy, blindness, and deafness. Although lack of
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an extended family to study precludes formal investiga-
tion of a digenic interaction, this remains a possible
explanation for the syndrome in this family.
Assigning pathogenicity of missense mutations in
Alstr€om syndrome is very challenging, partly because of
the very large number of rare missense alleles reported in
large publically available datasets such as the ExAC data-
set (Lek et al. 2016), and partly because no simple func-
tional assay exists with which to assess the consequence
of such variants. Two of the cases we describe, with typi-
cal Alstr€om syndrome, had the same missense variant,
p.Asn1787Asp, coinherited with either a frameshift or a
nonsense mutation. In one case no ALMS1 staining was
seen, while in the other staining was only equivocal. Thus,
although this variant is relatively common, being identi-
fied at an allele frequency of 1.4% in the Exome Aggrega-
tion Consortium (ExAC) dataset (Lek et al. 2016), and
although it is not predicted to be deleterious by a panel
of predictive algorithms, we suggest that it may confer
significant loss of function through destabilizing the
ALMS1 protein. In a second cell line the p.Asn2945Lys
variant, seen at 1% in ExAC, was found together with a
frameshift mutation, and ALMS1 expression was near
normal despite typical Alstr€om syndrome with the excep-
tion of visual acuity that remained at 6/36 at the age of
24 years old. This would be consistent with the
p.Asn2945Lys variant being expressed but dysfunctional,
although it is predicted to be benign by a panel of algo-
rithms. The formal possibility of linkage to an undetected
cis acting mutation in all three of these cases, or interac-
tion with a defect in a second gene, cannot be excluded,
however.
In the two patients with a prior clinical diagnosis of
Alstr€om syndrome but only missense variants in ALMS1,
ALMS1 expression in cells was normal. Furthermore, the
age of onset of cardinal features of Alstr€om syndrome
was strikingly later than in the rest of the cohort. Collec-
tively, these findings argue against pathogenicity of the
ALMS1 missense mutations previously said to be patho-
genic (Joy et al. 2007), and indeed in the one patient who
agreed to further evaluation with exome-wide sequencing,
an alternative genetic diagnosis, Bardet–Biedl syndrome
(BBS) due to convincing compound heterozygous splice
site mutations in BBS2, was established. Such overlap
between Alstr€om and Bardet–Biedl syndrome has previ-
ously been reported to lead to a significant degree of clin-
ical misclassification of the two disorders (Deveault et al.
2011; Redin et al. 2012).
Ciliogenesis requires a functional intraflagellar trans-
port (IFT) system to shuttle building proteins for con-
struction and maintenance of the cilium. Loss of IFT
complex protein(s) often results in short or absent cilia
(Ishikawa and Marshall 2011). Our observation that cilia
in all Alstr€om syndrome cell lines examined in this study
appeared normal confirms prior findings (Collin et al.
2005; Hearn et al. 2005; Jagger et al. 2011) and demon-
strates that ALMS1 is not required for ciliogenesis in der-
mal fibroblasts. While this could be taken to imply that
ALMS1 is not critically involved in the IFT cargo complex
as previously postulated (Girard and Petrovsky 2011), the
role of ALMS1 in ciliary formation and/or function may
be cell-type- and/or tissue-specific. Indeed knockdown of
ALMS1 in either retinal pigment epithelial cells (Graser
et al. 2007) or a mouse kidney epithelial cell line (Li et al.
2007) has been reported to produce stunted cilia without
affecting the efficiency of ciliogenesis, and homozygous
mutation of Alms1 in vivo in mice resulted in age-depen-
dent loss of cilia in the renal cortex (Li et al. 2007) and
reduced the number of hypothalamic neuronal cilia (Hey-
det et al. 2013). It remains possible that in humans, too,
these tissues exhibit abnormal ciliary structure.
The observation that Alstr€om patient cells showed nor-
mal GLI1 upregulation upon SHH and SAG stimulation
further suggests that ALMS1 is not critically involved in
the hedgehog signaling pathway in these cells. Similarly,
unhindered phosphorylation of MEK1/2 and AKT in
Alstr€om patient cells upon PDGF-AA stimulation suggests
that ALMS1 is also not critically involved in PDGFA sig-
naling pathway. This suggests that ALMS1 is dispensable
for signal transduction in at least some well-known cilia-
associated pathways. It has been noted, however, that cil-
iary localization is not a sufficient basis for assigning all
functions of a protein to the cilium (Yuan and Sun
2013). Many ciliary proteins, including IFT components,
are not exclusive to the cilium and have functions outside
of the organelle (Yuan and Sun 2013). Indeed, a recent
report demonstrated that ALMS1 might be involved in
the endosome recycling by interacting with a-actinin and
components of the endosome recycling pathway (Collin
et al. 2012). It is also interesting to note that primary
dermal fibroblasts from patients with Alstr€om syndrome
do show abnormal phenotypes related to extracellular
matrix formation and migration, although it remains
unclear whether these relate to ciliary or nonciliary func-
tions of the protein (Zulato et al. 2011).
In summary, our findings suggest that a large majority
of loss-of-function mutations in ALMS1 result in a failure
of protein expression, arguing that genotype–phenotype
correlations previously suggested are unlikely to hold.
Cells from occasional patients with biallelic loss of func-
tion ALMS1 mutations do exhibit preserved ALMS1
expression, however, and this corresponds to later onset
or more indolent course of some key components of the
syndrome. Our studies are consistent with the relatively
common missense variant p.Asn1787Asp conferring loss
or severe reduction in ALMS1 expression, suggest (but do
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not prove) that p.Asn2945Lys may be expressed but dys-
functional, but argue, conversely, that p.His624Arg,
p.His3881Tyr, and p.Val423Ile are not pathogenic. We
suggest that extreme caution should be exercised in
assigning pathogenicity to ALMS1 missense variants, and,
given the overlap in clinical features among different cil-
iopathies, that wider analysis of a ciliopathy gene panel is
warranted in any patient with features thought to denote
Alstr€om syndrome but without two convincing loss-of-
function ALMS1 mutations, especially where the pheno-
type is atypical or mild. In cases where this fails to yield a
convincing genetic diagnosis, immunostaining for ALMS1
in primary cells may have utility.
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